What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route.
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
FDA nonproprietary naming guidance for biological products · a recorded source, not a stored snapshot
What we know
RNAWiki holds 3 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
No description of who was studied is recorded.
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (11)
It was studied for a different goal
The studies measured something else entirely. Nothing in this record points to this reason.
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Prescription only
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No form or route is recorded.
No source is stored against this line.
Who oversees it
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Suppression classes recorded: S1, S3, S4.
No source is stored against this line.
What is in the pack
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing is recorded about product quality.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
The exact form studied is not recorded.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
1 published label names it as an active ingredient. None of them describes this substance alone, so no label text on this page can be attributed to it rather than to a combination.
US prescribing information · a617b089-ce66-464b-987b-b45d029b4d6f · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · a617b089-ce66-464b-987b-b45d029b4d6f · read 2026-08-29
107102 marketed supplement labels list this ingredient, classed as botanical with nutrients, multi-vitamin and mineral (mvm) and non-nutrient/non-botanical.
Those labels carry all other, nutrient and structure/function claims. A claim of that kind is written by the manufacturer and is not assessed by any regulator, so its presence says nothing about whether it is true.
Tecentriq Hybreza is subcutaneous at 3 DOSAGE FORMS AND STRENGTHS Injection: 1,875 mg atezolizumab and 30,000 units hyaluronidase per 15 mL (125 mg and 2,000 units per mL) clear to slightly opalescent, and colorless to slightly yellow solution in a single-…, recorded as fda label in effect 2026-05-20 in the United States.
US prescribing information · a617b089-ce66-464b-987b-b45d029b4d6f · read 2026-08-30
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.
Questions worth asking
Which of the trials of Atezolizumab and Hyaluronidase-Tqjs studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
How much did people take in the studies?
The sources RNAWiki checked hold nothing for this field.
Why it matters. A result belongs to an amount. Without the amount the result floats free.
What would answer it
A stored source that records it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Atezolizumab and Hyaluronidase-Tqjs are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
Where else this substance is registered
FDA substance identifier (UNII)
52CMI0WC3Y
CAS registry number
1380723-44-3
ChEMBL
CHEMBL3707227
WHO international nonproprietary name list entry
9814
RxNorm concept
1792776
EMA substance identifier
100000163921
DrugBank
DB11595
Checks this page had to pass
✓ Passed
Identity resolved
no open identity hold
✓ Passed
No unresolved merge across substance families
no quarantine open
✗ Not passed
Every public sentence names a source
The opening statement carries no source: the record holds neither an explanation nor a recorded use.
✗ Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
✓ Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
✓ Passed
Safety mode resolved
Suppression classes recorded: S1, S3, S4.
✓ Passed
Canonical metadata present
slug and display name present
What is missing or unclear◇Read from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
What the approval register records
1 approved application covers products containing this substance. The earliest was BLA761347, approved 20240912 to GENENTECH INC.
This order is fixed in code and does not count clicks or time on the page.
What is not here
9 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
What was measured, goal by goal — found nothing in the sources checked.
How close this is to real life — found nothing in the sources checked.
The path through the body — found nothing in the sources checked.
Felt, measured, or meaningful — found nothing in the sources checked.
How long anything takes — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (6)
Q2
139 registered trials of Atezolizumab and Hyaluronidase-Tqjs — at which phases?
Registered studies posting no result
92 of 139
139 registered studies of Atezolizumab and Hyaluronidase-Tqjs: 91 phase2, 49 phase1, 19 phase3, 3 early phase1, 1 phase4. CLINICALTRIALS_SNAPSHOT · 2026-09-01
0 with a PubMed record
Show the evidence
phase2
91
phase1
49
phase3
19
early phase1
3
phase4
1
completed
44
6 more recorded rows
active not recruiting
43
recruiting
24
terminated
17
withdrawn
8
suspended
2
unknown
1
recorded 2026-09-01 · last checked 2026-09-04
Q3
27 of Atezolizumab and Hyaluronidase-Tqjs's trials stopped: safety, accrual/recruitment, funding/business, sponsor decision unspecified, other?
safety (2), accrual/recruitment (12), funding/business (1), sponsor decision unspecified (1) and other (11): Atezolizumab and Hyaluronidase-Tqjs's stop wording, clustered. CLINICALTRIALS_SNAPSHOT · 2026-09-01
"Other - Assessing accrual feasibility"; 27 of 139 registered studies
terminated; "Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention."
NCT02322814
terminated; "Sponsor's decision"
NCT02400814
terminated; "Enrollment halted due to slow accrual."
NCT02495636
withdrawn; "Study closed due to lack of enrollment"
NCT02630186
terminated; "The study terminated before Phase 1 was completed. This study was reprioritized within the rociletinib development program."
14 further recorded trials
NCT02748889
terminated; "Difficulties with recruitment"
NCT02792192
terminated; "The study was terminated early as the study had met its goals of providing preliminary safety and efficacy information for atezolizumab monotherapy alone and in combination with BCG in NMIBC."
NCT03050060
terminated; "Terminated due to slow accrual"
NCT03199885
terminated; "Inadequate accrual rate"
NCT03272217
terminated; "Funder decision"
NCT03455556
terminated; "slow accrual"
NCT03786419
withdrawn; "Publication of study results of ICI use in MPM as first line therapy"
NCT04081688
terminated; "accrual goal met"
NCT04214418
terminated; "Toxicity and Lack of Efficacy"
NCT04249167
withdrawn; "study was dropped"
NCT04639245
terminated; "Terminated due to slow accrual."
NCT04902040
terminated; "PI requested."
NCT04989283
withdrawn; "Due to no accrual"
NCT05058651
suspended; "End of Initial Phase of Multi-phase protocol"
recorded 2026-09-01 · last checked 2026-09-04
Q4
Which running trial of Atezolizumab and Hyaluronidase-Tqjs could settle lifespan?
NCT02912559 measures Disease Free Survival (DFS), reading out 2026-12-18.
23 open trials; n 712; "Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair"
Show the evidence
Trial
NCT02912559
"Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair"; n 712; "Disease Free Survival (DFS)"; 2026-12-18
NCT05168163
"Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer"; n 122; "Overall survival (OS)"; 2026-12-31
NCT04334941
"Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker"; n 103; "Progression free survival"; 2027-01-21
NCT04402788
"Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial"; n 138; "Progression-free survival (PFS) (Phase II)"; 2027-04-30
NCT02997228
"Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study"; n 120; "Progression free survival (PFS)"; 2027-06-01
NCT03775265
"Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer"; n 475; "Bladder intact event-free survival (BI-EFS)"; 2027-06-01
14 further recorded trials
NCT04214262
"Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer"; n 415; "Overall survival"; 2027-06-09
NCT05836584
"Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer"; n 2; "Event-free survival (EFS)"; 2027-06-28
NCT04696575
"Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer"; n 28; "Progression-free survival"; 2027-07-01
NCT05411081
"Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial"; n 200; "Progression free survival"; 2027-07-01
NCT03181100
"Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer"; n 50; "Overall survival (OS) with targeted therapy + atezolizumab in cohorts 1 and 3 with anaplastic thyroid carcinoma (ATC)"; 2027-07-31
NCT05211323
"A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer"; n 4; "Progression free survival (PFS)"; 2027-08-10
NCT02849496
"Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer"; n 89; "Progression-free survival (PFS)"; 2027-08-26
NCT05063552
"Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers"; n 430; "Progression free survival (PFS) (Phase II)"; 2027-12-15
NCT05019703
"Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study"; n 40; "Progression-free survival (PFS)"; 2027-12-31
NCT05039281
"Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma"; n 47; "Progression-free survival (PFS)"; 2027-12-31
NCT03799835
"Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients"; n 517; "Event-Free Survival"; 2028-10
NCT06003621
"Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients"; n 96; "Progression Free Survival (PFS) rate at 6 Months"; 2028-11-01
NCT05394337
"Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma"; n 10; "To evaluate relapse-free survival (RFS)"; 2028-12-31
NCT03811002
"Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)"; n 544; "Overall Survival"; 2029-02-21
Q5
Which 16 trials of Atezolizumab and Hyaluronidase-Tqjs posted no result?
Posted no result
16 of 16 completed trials
Registrations
NCT01375842, NCT02463994, NCT02508870, NCT02814669, NCT02471846 and NCT02304393, and 10 more
Completion dates
oldest 2018-09-30; newest 2024-06-21
Show the evidence
Trial
NCT01375842
2018-09-30
NCT02463994
2018-11-07
NCT02508870
2019-06-10
NCT02814669
2019-07-31
NCT02471846
2019-10-02
NCT02304393
2019-11-07
10 further recorded trials
NCT02892318
2019-12-12
NCT02013219
2020-02-05
NCT01633970
2020-02-26
NCT02662309
2020-06-11
NCT03206047
2020-11-10
NCT02825940
2022-11-04
NCT03519295
2023-09-20
NCT02620280
2024-01-07
NCT02599454
2024-02-20
NCT05053737
2024-06-21
Q6
At the median, Atezolizumab and Hyaluronidase-Tqjs's trials enrolled 45 people — anything larger?
Median enrolment
45
Largest enrolment
1202
Registered trials counted
139
Q7
What do 4877 spontaneous reports say about Atezolizumab and Hyaluronidase-Tqjs — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Atezolizumab and Hyaluronidase-Tqjs appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 4877 reaction mentions were counted: pyrexia 932; pneumonitis 571; interstitial lung disease 521; febrile neutropenia 521. FAERS via Open Targets · CHEMBL3707227 · 2026-06-24
Show the evidence
pyrexia
932
pneumonitis
571
interstitial lung disease
521
febrile neutropenia
521
disease progression
510
hypothyroidism
421
4 more recorded rows
radiation pneumonitis
384
hepatic function abnormal
357
colitis
355
neutrophil count decreased
305
recorded 2026-06-24 · last checked 2026-09-04
Where it is registeredIdentifiers, relations and other names
ChEMBL 37 — CC BY-SA 3.0 Unported · ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Open Targets 26.06 — CC0 · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md
✗ required summary fields resolved: 3 required field(s) not terminal: Best-supported result, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 4 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.